Application status of rituximab in refractory nephrotic syndrome

doi:10.3877/cma.j.issn.2095-3216.2018.05.010

Abstract

Abstract:

Idiopathic nephrotic syndrome (INS) is a common glomerular disease in children and adults. Glucocorticoid is the basic drug for INS treatment. Most patients with idiopathic refractory nephrotic syndrome (IRNS) need to use other immunosuppressants or cytotoxic drugs on the basis of glucocorticoids. In recent years, some scholars have used rituximab (RTX) to treat IRNS and achieved good results. This article reviewed the pathogenesis of IRNS and the application of RTX in different pathological types.

Key words: Rituximab, Refractory nephrotic syndrome

Zhongxin Jin, Yufeng Qiao. Application status of rituximab in refractory nephrotic syndrome[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2018, 07(05): 234-237.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2018.05.010

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2018/V07/I05/234

References 32

[1]	王海燕．肾脏病临床概览[M]. 北京：北京大学医学出版社，2009：121-127.
[2]	Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis [J]. Kidney Inter Suppl, 2012, 2(1): 139-274.
[3]	傅君舟．成人难治性肾病综合征治疗的免疫抑制剂选择[J/CD]. 中华肾病研究电子杂志，2015，4(6)：281-285.
[4]	Manrique J, Cravedi P. Role of monoclonal antibodies in the treatment of immune-mediated glomerular diseases [J]. Nefrologia, 2014, 34(3): 388-397.
[5]	Mallat SG, Itani HS, Abou-Mrad RM, et al. Rituximab use in adult primary glomerulopathy: where is the evidence? [J]. Ther Clin Risk Manag, 2016, 12: 1317-1327.
[6]	何维，医学免疫学第二版[M]. 北京：人民卫生出版社，2010：177-178.
[7]	张英楠，涂阳科．利妥昔单抗应用于原发性膜性肾病的研究进展[J]. 中国新药与临床杂志，2016，35(5)：305-310.
[8]	Perez-Callejo D, Gonzalez-Rincon J, Sanchez A, et al. Action and resistance of monoclonal CD20 antibodies therapy in B-cell non-Hodgkin lymphomas [J]. Cancer Treat Rev, 2015, 41: 680-689.
[9]	付平，苟慎菊．利妥昔单抗在肾脏疾病中的应用[J]. 肾脏病与透析肾移植杂志，2017，26(1)：50-51.
[10]	Ruggenenti P, Ruggiero B, Cravedi P, et al. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome [J]. J Am Soc Nephrol, 2014, 25(4): 850-863.
[11]	Munyentwali H, Bouachi K, Audard V, et al. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease [J]. Kidney Int, 2013, 83(3): 511-516.
[12]	Niu XL, Hao S, Wang P, et al. Single dose of rituximab in children with steroid-dependent minimal change nephrotic syndrome [J]. Biomed Rep, 2016, 5(2): 237-242.
[13]	Sinha A, Bhatia D, Gulati A, et al. Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome [J]. Nephrol Dial Transplant, 2015, 30(1): 96-106.
[14]	Roccatello D, Sciascia S, Di Simone D, et al. New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: a prospective study and a review of the literature [J]. Autoimmun Rev, 2016, 15(6): 529-538.
[15]	李英，利妥昔单抗在特发性膜性肾病中的应用[J]. 肾脏病与透析肾移植杂志，2017，26(1)：54-55.
[16]	Dahan K, Debiec H, Plaisier E, et al. Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up [J]. J Am Soc Nephrol, 2017, 28(1): 348-358.
[17]	Suyama K, Kawasaki Y, Miyazaki K, et al. Rituximab and low-dose cyclosporine combination therapy for steroid resistant focal segmental glomerulosclerosis [J]. Pediatr Int, 2016, 58(3): 219-223.
[18]	Ronco P, Debiec H. Pathophysiological advances in membranous nephropathy: time for a shift in patient′s care [J]. Lancet, 2015, 385(9981): 1983-1992.
[19]	Ma H, Sandor DG, Beck LH Jr. The role of complement in membranous nephropathy [J]. Semin Nephrol, 2013, 33(6): 531-542.
[20]	Wang X, Cui Z, Zhang YM, et al. Rituximab for non-responsive idiopathic membranous nephropathy in a Chinese cohort [J]. Nephrol Dial Transplant, 2018, 33(9): 1558-1563.
[21]	Vivarelli M, Massella L, Ruggiero B, et al. Minimal change disease [J]. Clin J Am Soc Nephrol, 2017, 12(2): 332-345.
[22]	Madanchi N, Bitzan M, Takano T. Rituximab in minimal change disease: mechanisms of action and hypotheses for future studies [J]. Can J Kidney Health Dis, 2017, 4: 1-15.
[23]	Fornoni A, Sageshima J, Wei C, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis [J]. Sci Transl Med, 2011, 3: 85.
[24]	Königshausen E, Sellin L. Circulating permeability factors in primary focal segmental glomerulosclerosis: a review of proposed candidates [J]. Biomed Res Int, 2016, 2016: 376560.
[25]	Maas RJ, Deegens JK, Smeets B, et al. Minimal change disease and idiopathic FSGS: manifestations of the same disease [J]. Nat Rev Nephrol, 2016, 12(12): 768-776.
[26]	Magnasco A, Ravani P, Edefonti A, et al. Rituximab in children with resistant idiopathic nephrotic syndrome [J]. J Am Soc Nephrol, 2012, 23(6): 1117-1124.
[27]	Sadowski CE, Lovric S, Ashraf S, et al. A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome [J]. J Am Soc Nephrol, 2015, 26(6): 1279-1289.
[28]	Basu B, Mahapatra TK, Mondal N. Mycophenolate mofetil following rituximab in children with steroid-resistant nephrotic syndrome [J]. Pediatrics, 2015, 136(1): e132-e139.
[29]	Fujinaga S, Someya T, Watanabe T, et al. Cyclosporine versus mycophenolate mofetil for maintenance of remission of steroid-dependent nephrotic syndrome after a single infusion of rituximab [J]. Eur J Pediatr, 2013, 172(4): 513-518.
[30]	Cravedi P, Remuzzi G, Ruggenenti P. Rituximab in primary membranous nephropathy: first-line therapy, why not? [J]. Nephron Clin Pract, 2014, 128(3-4): 261-269.
[31]	Königshausen E, Sellin L. Recent treatment advances and new trials in adult nephrotic syndrome [J]. Biomed Res Int, 2017, 2017: 7689254.
[32]	Fujinaga S, Sakuraya K. Single infusion of low-dose ofatumumab in a child with complicated nephrotic syndrome with anti-rituximab antibodies [J]. Pediatr Nephrol, 2018, 33(3): 527-528.

Please choose a citation manager

Content to export